Moderna said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher efficacy in ...
Moderna's (MRNA) new COVID-19 shot, mRNA-1283, shows promising results in Phase 3 trials, with comparable efficacy and safety to its approved vaccine. Read more here.
CAMBRIDGE - Moderna announced Monday that its combination COVID and flu vaccine showed positive results in a late-stage trial ...
There are still multiple steps required before the shot would become available. Moderna's combo flu and COVID vaccine provided a strong immune response in older adults, with levels comparable to ...
Moderna announced its combination Covid and flu vaccine generated stronger immune responses in older adults in a Phase 3 ...
Trial data suggest the shot — an important component of an upcoming combination inoculation — has proven at least as effective, and in some cases superior, to the company’s initial COVID vaccine.
, opens new tab said on Thursday its next-generation COVID-19 vaccine candidate showed it was not inferior in efficacy compared to its approved shot in a late-stage study. The experimental vaccine ...
Moderna's combo flu and COVID vaccine provided a strong immune response in older adults, with levels comparable to getting the flu and COVID shots separately, according to the company's results ...
A consistent trend was seen in a subset of adults aged 65 and older Moderna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher efficacy ...